Please provide your email address to receive an email when new articles are posted on . Laru-zova demonstrated a positive safety profile and early efficacy in improving low luminance visual acuity in ...

Please provide your email address to receive an email when new articles are posted on . Facial identity discrimination accuracy decreased by 20.4% under low luminance for those with central vision ...

Oral gildeuretinol demonstrated a statistically significant reduction in the geographic atrophy (GA) lesion growth rate of 15.3% from 6 to 24 months (p=0.047) in a pre-specified analysis.

LONDON and CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a ...

Data showed sustained improvements across several key measures of visual function, including low luminance visual acuity and microperimetry Laru-zova was generally well-tolerated by SKYLINE ...

The only approved ocular gene therapy, which targets a specific gene mutation in two forms of inherited retinal disease, has shown evidence in a real-world study from the United Kingdom that young ...

Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry Laru-zova was generally well-tolerated by DAWN participants at 6 ...